{
  "id": 8665212,
  "title": "Cue Biopharma reports positive phase 2 results for CUE-221",
  "url": "https://urgent.news/2026/09/20/cue-biopharma-reports-positive-phase-2-results-for-cue-221",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-20T10:04:46.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/cue-biopharma-reports-positive-phase-2-results-for-cue221-93CH-4908155"
  },
  "original_language": "en",
  "account": "Boston - Cue Biopharma disclosed favorable outcomes from a Phase 2 trial of their drug CUE-221 for chronic spontaneous urticaria, conducted by Genesis Life Sciences in China. The study, which involved 145 patients with moderate to severe urticaria not responding to H1 antihistamines, spanned 16 weeks of treatment followed by 20 weeks of observation. Participants were divided into five groups, receiving CUE-221 at varying doses, a placebo, or omalizumab. The primary outcome, resolution of hives measured by HSS7=0 at week 12, was achieved at all dose levels with significance, most notably at the 4 mg/kg dose which resulted in 54% complete resolution compared to 11% for placebo and 41% for omalizumab. The secondary measure, UAS7=0 at week 12, reached statistical significance at the 4 mg/kg dose with 46% of patients achieving complete resolution, compared to 11% for placebo and 29% for omalizumab. The positive effects of CUE-221 continued beyond week 12, with the 4 mg/kg group maintaining a 60% resolution at week 28, compared to 24% for omalizumab. The drug showed a favorable safety profile, with no serious adverse events or hypersensitivity reactions reported. Cue Biopharma plans to follow up with Phase 2b/3 studies in chronic spontaneous urticaria and a Phase 2 study in food allergy. A conference call will be held Monday at 8:00 a.m. EDT to present these results.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}